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Inflammatory idiopathic myopathies are a group of autoimmune diseases affecting predominantly 
the proximal skeletal muscles, with raised muscle enzymes, with or without skin involvement and 
extramuscular organ involvement. Autoantibodies help to characterise patients into different clinical 
phenotypes. Successful treatment necessitates controlling inflammation early with corticosteroids 
and invariably requires additional immunosuppressive therapy.  
This review focuses on the aetiology, pathogenesis, clinical presentation, investigations and 
management of patients presenting with inflammatory idiopathic myopathies, predominantly 












Inflammatory idiopathic myopathies (IIM) are a group of rare autoimmune diseases characterised by 
proximal skeletal muscle weakness, raise muscle enzymes (e.g. creatine kinase (CK)), and 
extramuscular organ involvement, most frequently the lungs, resulting in interstitial lung disease 
(ILD). Numerous autoantibodies are associated with the disease, many linked to different clinical 
phenotypes. This review focuses on the adult-onset IIM, polymyositis (PM), immune-mediated 
necrotising myopathy and dermatomyositis (DM) (inclusion body myositis is beyond the scope of this 
article).  
PM predominantly presents with proximal symmetrical muscle weakness, while DM is characterised 
by skin and muscle involvement, both are associated with extramuscular features.   
Epidemiology 
The incidence of DM and PM combined is 6-10 per million [1] with a peak incidence of 60-69 years 
and 50-59 years in PM and DM respectively. The prevalence is approximately 2 and 8 per 100,000 
from both single centre and multicentre data [1,2]. The combined female to male ratio is 2:1 [3], but 
when split by disease, DM it is 2.1:1 and in PM 1.6:1 [1].  
In a UK study, 69.6% of patients were Caucasian, 13% Afro-Caribbean, 13% Asian and 4.3% other [4]. 
World-wide, however, there is a higher incidence of inflammatory myositis in black patients 
compared to white. 
Diagnostic Criteria 
The Bohan and Peter set out diagnostic criteria for PM and DM which remain widely used (Table 1) 
[3]. The revised diagnostic criteria by Targoff in 1997 includes the muscle specific antibodies [5] and 
maintains sensitivity of diagnosis, but improves specificity from 23% to 62% [6]. 
Aetiology 
The aetiology of IIM is multifactorial and a combination of environmental and genetic risk factors.  
Environmental risk factors  
Infectious agents (e.g. Coxsackie virus B, cytomegalovirus and toxoplasmosis[7]), as well as foods, 
medication and vaccinations have been implicated in the development of IIM, although studies are 
often conflicting. Medications include D-Penicillamine, fibrates, 3-hydroxy-3methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors, hydroxyurea, L-Tryptophan [causes an eosinophilia 
myalgia syndrome] and Ciguatera toxin. Vaccines linked with myositis are DTP (diphtheria-typhoid-
pertussis), MMR (measles-mumps-rubella), BCG (Bacillus Calmette–Guérin), influenza, hepatitis A/B. 
Occupational exposure to silica and cyanoacrylate glue may also be associated with myositis, as is UV 
light, chimerism and graft vs host disease [7].  
Genetic risk factors 
Although no one gene has been identified as underlying cause of IIM, genetic risk factors are 
associated with IIM. These include HLA alleles found on chromosome 6 (most specifically HLA-
DQA1*0501 and HLA-DRB1*0301 [8,9]). Polymorphisms in the tumour necrosis factor α (TNF-α) 
gene encoding region [9] are correlated with longer disease course and increased disease severity. 
Pathology/pathogenesis  
Both adaptive and innate immune pathways are implicated in the development of IIM. Although 
there are many similarities, PM and DM demonstrate distinct immunohistopathological phenotypes, 
suggesting the underlying pathogenesis may not be the same.  
The immune-mediated necrotizing myopathies (IMNM) have very little inflammatory infiltrate on 
biopsy, necrosis is the predominant finding [10,11].  
Innate immune mechanisms drive the pathology, including pro-inflammatory cytokines such as 
interleukin (IL)-1α, type 1 interferon (IFN) and TNF-α. IL-1α can persist in the absence of other 
inflammatory infiltrates, suggesting it contributes to the persisting weakness even after the 
inflammation is controlled [12].  
MHC class 1 antigens are upregulated in IIM in response to type 1 IFN, a finding not seen in normal 
muscle fibres [12]. This upregulation may make the muscle fibres targets for CD8+ cytotoxic T cells 
and contribute to muscle fibre destruction. This upregulation precedes the lymphocytic infiltrates 
into the muscle fibres on biopsy [13].  
MHC class 1 antigen expression has a predominantly perifascicular accentuation in DM and 
antisynthetase syndrome (ASS), but has a more confluent distribution seen in PM [14,15].  
DM characteristically demonstrates complement-mediated vasculopathy of the small vessels. 
Ischaemia and muscle damage are the result of deposition of C5b-9 membrane attack complexes 
around the microvasculature. Histologically, there are mononuclear inflammatory cell infiltrates 
(predominantly B cells and CD4+ T cells) within the muscle fibres, distributed in a perivascular and 
perfascicular distribution. There is usually evidence of degenerating and regenerating muscle fibres 
[16,17]. Ischaemic microangiopathy may give rise to perifascicular atrophy of the myofibrils. The 
presence of B cells and CD4+ T cells suggest a humorally mediated pathogenesis. 
Biopsies from patients with PM characteristically exhibit CD8+ cytotoxic T cells surrounding non-
necrotic muscle fibres [16,17]. This appearance results in muscle fibre necrosis and regeneration. 
The microvasculature remains intact, and the presence of B cells is extremely rare. These features 
suggest that the disease is cell mediated. The CD8+ T cells and macrophages clonally expand, and 
interact with the MHC class 1 expressing muscle fibres, driving the muscle fibre changes in the 
endomysium.  
Autoantibodies are positive in up to 80% of patients with IIM [18,19], with ANA being the most 
common [24-60%]. Autoantibodies to extractable nuclear antigens (ENA) (including anti-Ro, anti-La, 
anti-Smith, anti-RNP and anti-Scl70) if present suggest an overlap condition with another 
autoimmune rheumatic disease (ARD). Muscle specific antibodies (MSAs) include anti-SRP and anti-
Jo-1 help confirm the diagnosis.  
Antisynthetase antibodies 
Antisynthestase syndrome (ASS) is characterised by antisynthetase antibodies, that bind directly to 
the aminoacyl transfer RNA synthetases, a group of enzymes that catalyse the binding of a specific 
amino acid to the cognate tRNA during protein synthesis. These antibodies are highly specific for 
IIM, and can be detected prior to disease onset. The antisythetase antibodies are the most 
commonly identified MSAs. They are found in 35-40% of patients with IIM [20] (Table 2) and have a 
distinct phenotype. 
Necrotising myopathy is a subset of IIM, and is associated with a different group of antibodies, 
notably those binding the signal recognition particle (SRP). Their presence suggests an antibody-
mediated mechanism, with a possible drug trigger, viruses, cancer, and other ARDs [10,21]. Statins 
are specifically known to cause a statin-induced necrotizing myopathy, especially in the presence of 
an antibody against HMG-CoA reductase. Biopsies demonstrate CD3 lymphocytes and CD68 
macrophages around the necrotic and regenerating muscle fibres.  
Clinical features 
Muscle Weakness 
The classical presentation of IIM is symmetrical, bilateral, proximal muscle weakness, and is the 
presenting symptoms in 84% of patients, while myalgia is seen in up to 75% of patients at 
presentation [1]. Up to 97% of patients have evidence of muscle weakness during the course of their 
disease [1]. Patients often report difficulty in combing hair or reaching for objects above their head 
with upper limb muscle involvement. Lower limb involvement typically presents with difficulty 
standing up from a chair, or walking up stairs.  
Antisynthetase Syndrome (ASS) 
Patients with ASS often have very specific features linked to the antibody present in their serum 
(Table 2). ILD is frequently found, as are inflammatory arthritis, fever, mechanics’ hands and 
Raynaud’s Phenomenon (RP) [22]. Anti-Jo-1 antibody is the most common AS antibody detected.  
IMNM-specific phenotypes 
Anti-SRP antibodies present with a rapidly progressive myopathy and noticeable dysphagia [23]. 
These patients are less responsive to immunosuppression and have a poorer long term outcome.  
There is suggestion that antibodies against HMGCR are triggered by statin exposure [24], especially 
in HLA-DR11 carriers.  Weakness can persist even after the medication is withdrawn. The antibody 
concentration correlates with serum CK [11]. 
Rash 
A rash is one of the defining features of DM and is typically found in a photosensitive distribution. 
The characteristic manifestations of DM rashes include a violaceous discolouration around the eyes 
[heliotrope], predominantly the upper eyelids, often with associated periorbital oedema. Gottren’s 
papules are found over the extensor surface of the metacarpophalangeal (MCP) joints or the 
interphalangeal (IP) joints and appear as symmetrical palpable erythematous lesions. The typical 
mechanics’ hands present as hyperkeratosis, and painful fissuring of the skin at the tips and sides of 
the fingers. These are most typically found in the patients with ASS. Patients can also present with 
macula erythema either in the distribution of the lower anterior neck and upper anterior chest (the 
V sign), or in a shawl distribution (Shawl sign).  Periungal erythema is more common in the juvenile 
DM cohort than adult. Capillaroscopy demonstrates abnormal tortuous nailfold capillaries.  
Antibodies in DM are highlighted in Table 2.  
Other clinical features 
GI tract 
Dysphagia is a presenting feature in about 25% of patients, but will eventually affecct 60% of 
patients [1]. Patients can also develop dysphonia and even aspiration pneumonia as a result of 
pharyngeal weakness, and upper oesophageal dysmotility [25].  
Patients with anti-SRP are more likely to develop refractory dysphagia [26] compared to the other 
forms of myositis.  
Respiratory 
ILD is found in up to a third of patients with IIM, and 95% of patients with ASS [27,28]. This feature is 
most specifically seen in patients with anti PL-12, anti-KS and anti-OJ antibodies [20,29]. 70% of anti-
Jo-1 patients have associated ILD. It can either present subclinically (through screening) or with 
dyspnoea on exertion and a non-productive cough. Muscular weakness contributes to symptoms 
with dysphagia predisposing to aspiration pneumonia, or respiratory muscle weakness. Nonspecific 
interstitial pneumonitis (NSIP) is the commonest finding on imaging, but usual interstitial 
pneumonitis (UIP) is also regularly identified. NSIP carries a better prognosis, being more responsive 
to immunosuppression. 
Rapidly progressive ILD is seen in patients with anti MDA-5 antibodies [28], often with subclinical 
myopathy.  
Patients with ILD are at a higher risk of developing pulmonary hypertension or cor pulmonale, and 
require regular screening with pulmonary function tests and echocardiograms.  
Joints 
Arthritis is a relatively common symptom in IIM, and can predate the muscle weakness by years. It is 
a presenting feature in 20-30% of patients [30,31]. Typically, it presents as a symmetrical 
polyarthritis mainly affecting the MCP joints, proximal IP joints, wrists and knees [32].  
Inflammatory arthritis, is more common in patients with ASS, especially those with anti-Jo-1 
antibodies (75%) [33]. About 55% of patients with anti-Jo-1 ASS associated arthritis develop a 
symmetrical polyarthritis without erosions [34], 25% an isolated arthralgia, and 15-19% develop a 
subluxing arthropathy mainly of the distal interphalangeal joint and IP joint of the thumb [typically 
nonerosive] [35]. Erosions are rare in ASS, unless patients are rheumatoid factor (RF) positive [33], or 
have anti-PL7 antibodies [34].  
30% of patients with anti-Jo-1 ASS are anti-CCP (cyclic citrullinated peptide) positive, and 13.5% are 
also RF positive. Nearly all patients with anti-CCP antibodies and IIM develop arthritis [35] and have 
significantly more articular damage on plain radiograph compared to ASS patients without the 
antibodies (87% and 11% respectively) [35].  
Raynaud’s  Phenomenon 
RP affects 40%-60% of IIM patients, and more commonly in DM than PM (39% and 19% respectively 
[1]). There is a higher prevalence of RP in ASS patients[36,37]. About 50% of patients with anti-Jo-1 
myositis also have RP [34], which can precede muscle weakness by a median of 13 months [IQR 12-
48 months][38]. Capillaroscopy usually confirms nailfold abnormalities and thermography 
demonstrates slow rewarming [34].  
Constitutional symptoms 
Constitutional symptoms, mainly weight loss [50%), and fevers (55%) [39]precede the diagnosis of 
dermatomyositis in nearly 50% of patients [39], and are reported in up to 72% of anti Jo-1 ASS [40]. 
Fever is more likely at the onset of the disease, or with disease relapse [32], than at other times. 
Cardiac 
Cardiac abnormalities are extremely rare in IIM. These include conduction defects, congestive 
cardiac failure, pericarditis, and valvular heart disease [41]. Mortality is often secondary to right 
heart failure in the context of ILD.  
Cardiac involvement is more frequently seen in anti-SRP patients compared to other phenotypes 
[23]. Asymptomatic arrhythmias have rarely been reported in DM [42].  
Overlap conditions 
Myositis can be found in combination with other ARDs.  
Anti-Ku antibodies are found in 55% of patients with PM/SSC (systemic sclerosis) overlap syndrome, 
and 20-30% of patients with IIM in total[20].  
Nearly 50% of overlap myositis-systemic sclerosis patients[20], have antibodies to anti-PM-Scl 75 
and anti-PM-Scl 100. These patients tend to have both lung and oesophageal involvement.  
Other antibodies include Anti-Ro (10-20% of IIM), and anti-La (5%) and anti-U1RNP (20-30%) which 
are more often found in systemic lupus erythematosus (SLE) (up to 4% of SLE patients have 
concomitant myositis), and Sjogren’s syndrome[18].  
Important differential diagnoses 
Non-inflammatory myopathies must be excluded. They include muscular dystrophy of late onset, 
limb-girdle dystrophy with adult onset, and myotonic dystrophy type 2.  
Mitochondial myopathies can present with proximal muscle weakness and a raised CK, and 
emphasise the need for a muscle biopsy in order to differentiate between these diagnoses.  
Drug induced myopathies (e.g. D-Penicillamine, Interferon) remain in the differential. HMG-CoA-
reductase inhibitors (commonly known as statins), are one of the commonest medications to cause 
myalgia with a normal CK as a side effect (affecting 1-10% of patients) [43]. Rhabdomyolysis is 
devastating but rare, affecting less than 0.1% of patients. Statin-related myopathy is more 
commonly seen in those that are hypothyroid, patients on multiple medications (especially inhibitors 
of the cytochrome p450 group of enzymes), and those that abuse alcohol. Upon stopping a statin, 
symptoms can persist for up to 6 months. 
Endocrine myopathy including hypo or hyperthyroidism, and hyperparathyroidism can present with 
proximal weakness. 
Muscular dystrophy is a group of progressive myopathic disorders caused by genetic defects. 
Although biopsies taken from these patients may initially show endomysial inflammatory cell 
infiltrate, this tends to be limited to areas adjacent to necrotic muscle fibres, unlike PM [44].  
Metabolic myopathies are inherited myopathies associated with abnormalities in carbohydrate and 
lipid metabolism. These include conditions such as carnitine deficiency and myoadenylate 
deaminase deficiency. Patients present with episodes of acute muscle pain and tenderness, with or 
without association myoglobinuria, often triggered by exertion. This can lead to chronic weakness 
with repeated episodes [44].  
Infectious myopathies are often triggered by an acute viral illness such as coxsackie virus or influenza 
virus. Human immunodeficiency virus (HIV) can also be associated with weakness either as a 
presenting feature or at late stages in the disease. Patients present with muscle tenderness and 
elevated muscle enzymes which is hard to distinguish from PM, but the biopsy tends to have fewer 
inflammatory infiltrates [44].  
Investigations 
Bloods 
Initial laboratory tests include full blood count, inflammatory profile including erythrocyte 
sedimentation rate, C-reactive protein, thyroid-stimulating hormone and free thyroxine 4, 
electrolytes (sodium, potassium, creatinine, magnesium, calcium, phosphate, magnesium), lactate 
dehydrogenase, liver function tests (aspartate aminotransferase, alanine aminotransferase) and CK. 
Immunoglobulins and protein electrophoresis are useful, as well as a full viral screen including HIV, 
hepatitis B and hepatitis C serology. Autoantibodies including ANA, ENA and muscle specific 
antibodies (MSA) should be checked. 
Whereas the majority of patients with IIM present with a raised CK, those with IMNM may have CK 
levels more than 10 times the upper limit of normal.   
Anti-HMGCoA reductase antibodies have been found to correlate strongly with disease activity and 
CK, and a decrease in antibody titre is associated with improved arm strength and CK levels [11].  
Muscle biopsy 
This remains the gold standard for confirming the diagnosis of IIM, distinguishing from a necrotising 
and inflammatory biopsy, and excluding a non-inflammatory myopathy.  
The biopsy findings of PM and DM have already been discussed. On biopsy, patients with ASS 
demonstrate prominent perimysial inflammation with fragmentation and perifascicular myopathic 
changes [45]. 
Patients with anti-SRP antibodies demonstrate characteristic biopsy changes of muscle fibre necrosis 
and endomysial fibrosis with little inflammatory infiltrate visible [23,26]. 
Skin biopsies are occasionally utilised to confirm DM, especially when the muscle biopsy is 
indeterminate. 
Neurophysiology 
Electromyography (EMG) is a useful means of distinguishing a myopathy from a neuropathy. It is 
abnormal in around 90% of patients presenting with IIM [4]. 
EMG findings include polyphasic motor unit action potentials of short duration and low amplitude, 
coupled with increased insertional and spontaneous activity with fibrillation potentials, sharp waves, 
and occasionally repetitive discharges.  
Muscle imaging 
Magnetic resonance imaging (MRI) is increasingly used as the imaging modality of choice for 
confirming IIM. It aids in choosing sites of maximal inflammation for biopsy, and to monitor 
treatment response. It is also a sensitive means of differentiating acute inflammation from muscle 
atrophy and chronic muscle damage.   
Diagnosing ILD 
Given the multisystem nature of IIM, a baseline chest radiograph and pulmonary function tests are 
important at the time of diagnosis.  
Pulmonary function tests can also give an idea of the extent of weakness, especially if there are 
reduced inspiratory pressures, or poor effort due to respiratory muscle weakness. This weakness will 
put the patient at risk of aspiration pneumonia. Reduced diffusing capacity suggests a fibrotic 
process. High resolution Computed tomography [CT] is then utilised in order to confirm NSIP with 
ground-glass opacities without honeycombing (the most common abnormality noted in lung disease 
in IIM).  
Cancer screening 
Up to 25% of patients with DM develop a malignancy within 0-5 years of disease onset, whereas this 
association is only 10-15% in patients with PM [46]. The risk factors include male gender, older age 
at disease onset, extensive skin or muscle involvement, elevated inflammatory markers, and 
negative ANA and MSAs or positive for anti TIF1ɣ (accounts for over 50% of adult patients with 
cancer-associated DM [47]). The risk is reduced in those with ASS or overlap syndrome. The most 
frequent IIM associated malignancy are breast and ovary in women, lung and prostate in men, as 
well as pancreatic, gastric, colorectal, bladder cancer and non-Hodgkin lymphoma [46]. 
There are no clear guidelines of how or when to screen patients for malignancy. Our practice is a 
focus on the patient’s history (especially a history or weight loss and constitutional symptoms) since 
the last clinic appointment, and to have a low threshold for a chest radiograph and  abdominal 
ultrasound, or if clinical suspicion is high- positron emission tomography scan.   
Treatment/Management 
The main aims of treatment are to suppress inflammation, improve muscle power and prevent 
chronic damage to muscles and extramuscular organs. However there is a lack of robust data to 
guide treatment. Most studies are based on observational data, or on small randomised control 
trials. Our centre’s treatment algorithm is shown in Box 1. 
Glucocorticoids remain the mainstay of treatment in IIM [48]. Initial dosing is approximately 0.5 
mg/kg of prednisolone, but the many side effects of steroids encourage a reducing regime over the 
first two months. Disease relapse with rapid reduction of prednisolone [49] results in the need for 
steroid-sparing agents. Severe weakness unresponsive to oral prednisolone requires intravenous 
methylprednisolone at a dose of 500mg to 1g daily for 3 days, prior to switching to an oral dose of 
prednisolone. These patients may require a slower steroid reduction.  
Methotrexate and azathioprine are often used as first line disease modifying agents (DMARDS). A 
Cochrane review found insufficient evidence of improved efficacy using one DMARD [methotrexate, 
azathioprine or cyclosporine] in combination with corticosteroids in preference to another. 
Methotrexate showed similar improvement in both DM and PM in composites score of muscle 
endurance and function. This was not statistically different from azathioprine in a head to head trial 
[50].  
If azathioprine is chosen as first line, then thiopurine methyltransferase levels should be checked 
prior to screen for enzyme deficiency. Those that are deficient have an increased chance of 
myelosuppression. The dose used is 2-2.5 mg/kg [51]. Azathioprine and Methotrexate can also be 
used in combination where either agent alone has not proved effective [52]. 
Mycophenolate mofetil (MMF) is increasingly being chosen as an effective treatment for myositis, in 
both severe DM and PM. Improvement in skin disease, and muscle strength are seen in patients who 
have not responded to conventional treatment [53,54]. Small studies have suggested MMF also 
benefits pulmonary function tests in patients with DM and ILD [55].  
Cyclophosphamide may be useful in patients with ILD and severe myopathy [56,57]. Up to 70% of 
patients with ILD improve both symptomatically and when measured on their FVC (by at least 15% 
from baseline)[56]. The intravenous form is favoured due to fewer side effects, and typically 500 to 
750 mg is given in monthly doses over 6 months.  
There is limited supporting evidence for intravenous immunoglobulin (IVIg) in both refractory PM 
and DM to conventional DMARDS [58,59]. However it is expensive and usually provides only short 
lived benefit. Cherin et al showed 75% response rate in muscle power, and 90% biochemical 
improvement [59]. It is typically administered at a dose of 2g/kg usually spread over three days on a 
monthly basis for three months, provided a response to the treatment is seen.  
Rituximab has been shown to be effective in patients with refractory disease, as defined by failure to 
control disease on at least one immunosuppressive agent for a duration of at least 3 months. A 
recent review 78.3% of patients refractory to conventional treatment responded to rituximab [60] 
(when assessing muscle power, lung function and skin manifestations). MSAs (especially anti-Mi-2 
antibodies and anti-Jo-1 antibodies) were associated with a 3 x higher chance of improvement 
compared to patients without any autoantibodies, when treated with rituximab [61]. The long term 
data also suggests that long-term remission for >12 months can be achieved. Fasano et al [60] 
highlighted the beneficial effect of Rituximab specifically in patients with ILD, the CTD-ILD patients 
responding optimally [62].  
In one study only 52% of patients (n= 151) with DM and significant skin disease responded to 
Rituximab and the relapse rate was high (48.6%)[60]. The heliotrope rash, erythroderma, Gottron 
sign and violaceous poikiloderma were most responsive to rituximab [63,64]. Paraneoplastic skin 
lesions did not generally improve.  
Cyclosporine and Tacrolimus have a role in the treatment of IIM with ILD [65]. There is also some 
evidence that cyclosporine may induce partial regression of calcinosis [66]. 
Anti-TNF agents seem to be of little benefit. Furthermore studies consistently demonstrate the 
association of Anti-TNF agents with the onset of other auto-immune diseases including cutaneous 
vasculitis, lupus-like syndrome, SLE, and interstitial lung disease [67,68]. 
It is vital to reinforce the necessity to avoid UV rays, and to promote the use of at least factor 50 
sunblock. Topical corticosteroids, hydroxychloroquine and topical tacrolimus (0.1%) [69] are often 
used to control the cutaneous manifestations.  
Although calcinosis is extremely rare in the adult population, it remains a challenge to treat. Small 
improvements are anecdotally reported with diltiazem, colchicine, cyclosporine and 
bisphosphonates.  
Monitoring response 
The International Myositis Assessment and Clinical Studies Group have suggested core measures to 
monitor inflammatory myositis. These include Global activity, muscle strength, physical function, 
laboratory assessment and extramuscular disease.  
It is critical to distinguish active disease (requiring further immunosuppression) from permanent 
damage or another concomitant condition. Scoring systems are means of helping to assess 
improvement, stability or deterioration in symptoms.  
ACR/EULAR have developed a set of criteria to monitor response based on 6 core set measures 
[physician, patient, and extramuscular global activity, muscle strength, Health Assessment 
Questionnaire, and muscle enzyme levels], with a total improvement score classifying patients into 
minimal, moderate and major improvement groups [70]. Although mainly designed for trials, they 
can also help guide therapeutic response, and need for intervention.  
Physiotherapy is mainly advised in the acute phase to maintain full range of joint movement. It is 
encouraged as patients start to recover, and full remission is not required for active therapy.  
Prognosis and Future prospects 
Due to the delayed presentation of the non-Jo-1 PM, currently there is increased pulmonary 
morbidity and mortality in this cohort of patients compared to the anti-Jo-1 patients [71].  
In our centre, over a 37 year period, 36.1% of patients had a monophasic disease course, 34% a 
relapsing and remitting, and 29.9% were defined as chronic persistent. 24.7% of patients died most 
commonly from infection (29.2%). Cumulative survival at 5 years was 94.6%, and at 10 years 82.2% 
[72]. 
Potential biomarkers to monitor disease activity are emerging. In DM these include IL6 and type 1 
IFN genes. IL 6 regulates innate and adaptive immune responses, and has both B and T cell activity 
[73,74]. There is also evidence that Type 1 IFN has a role in DM, through activation of T cells, 
including NK cells and an influence on dendritic cell maturation. Thus anti IL^ therapy might be a 
possible treatment.  
 
 
Table 1: Bohan and Peter diagnostic criteria for polymyositis  [PM] and dermatomyositis [DM] 
Item Description 
1 symmetrical weakness of limb-girdle muscles and anterior neck flexors 
2 Muscle biopsy evidence typical of myositis 
3 Elevation of serum skeletal muscle enzymes, particularly CK 
4 Typical EMG features of myositis 
5 Typical DM rash, including heliotrope and Gottron's papules 
For the diagnosis of PM For the diagnosis of DM 
Definite All of items 1-4 Definite Item 5 plus 3 of items 1-4 
Probable 3 of items 1-4 Probable Item 5 plus 2 of items 1-4 
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